Memantine Monotherapy for Executive Dysfunction and ADHD

Inclusion Criteria:

1. Male and female adults ages 18-45 years;

2. a diagnosis of DSM-IV [78] ADHD-combined type

3. a score of at least 20 on the AISRS (a score of 20 in the AISRS identifies subjects
with at least moderate severity of symptoms);

4. a BRIEF-A Global Executive Composite T-score of >6; and

5. proficiency in English. -

Exclusion Criteria:

1) Pregnant or nursing females; 2) investigator and his/her immediate family (spouse,
parent, child, grandparent, or grandchild); 3) any serious, unstable medical illness
including hepatic, renal, gastroenterological, respiratory, cardiovascular (including
ischemic heart disease and hypertension), endocrinologic, neurologic, immunologic, or
hematologic disease; 4) hypersensitivity to memantine; 5) multiple adverse drug reactions;
6) current or past history of seizures; 7) any history of a major psychiatric disorder
including schizophrenia, psychosis, bipolar disorder (BPD), or autism spectrum disorder
(ASD); 8) meets DSM-IV criteria in the last month for major depression or any major
anxiety disorder or has a Hamilton Rating Scale for Anxiety (HAM-A) or Hamilton Rating
Scale for Depression (HAM-D) score greater than 14; 9) meets DSM-IV criteria for substance
abuse or dependence in the last month or has a positive drug urine screen; 10) judged to
be at serious suicidal risk; 11) use of any other concomitant medication with primarily
central nervous system activity; or 12) IQ < 80.

-